12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

JX-594: Phase I/IIa started

Molecular target: Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)

Description: Recombinant vaccinia virus (addition of granulocyte macrophage colony-stimulating factor (GM-CSF) and deletion of thymidine kinase)

Indication: Treat metastatic colorectal cancer (mCRC)

Endpoint: Maximum tolerated dose (MTD), safety and response rate as measured by RECIST...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >